1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. Company
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
Delayed Australian Stock Exchange  -  05/20 02:10:09 am EDT
275.17 AUD   +0.43%
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
05/11Australian shares rise on healthcare, mining boost; U.S. inflation data in focus
RE
05/06Australia shares slump as inflation woes hint at more rate hikes
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo CSL Limited
CSL Limited (CSL) is a biotechnology company engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. CSL provides a portfolio of life saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Its segments include CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.

Number of employees : 25 000 people.
Sales per Business
20202021Delta
CSL Behring11 715.4085.8%11 493.9083.2% -1.89%
Seqirus1 934.8914.2%2 327.5216.8% +20.29%
AUD in Million
Sales per region
20202021Delta
United States6 859.1750.2%6 680.7948.3% -2.6%
Rest of World2 976.1021.8%2 782.9120.1% -6.49%
Australia1 122.218.2%1 151.698.3% +2.63%
Germany1 232.009%1 144.998.3% -7.06%
China321.162.4%872.596.3% +171.69%
United Kingdom713.335.2%776.875.6% +8.91%
Switzerland426.333.1%411.563% -3.46%
AUD in Million
Managers
Name Title Age Since
Paul Perreault Chief Executive Officer, Executive Director & MD 63 2013
Joy Linton Chief Financial Officer 56 2020
William Mezzanotte Chief Medical Officer, EVP & Head-R&D - 2018
Mark Hill Chief Digital Information Officer - 2020
Paul McKenzie Chief Operating Officer - 2019
Mark Dehring Vice President-Investor Relations - -
Fiona McCallum Mead Secretary & Head-Corporate Governance - 2018
Andrew Nash, Dr. Senior Vice President-Research - 2006
Bill Campbell Chief Commercial Officer & Executive VP - 2017
Gregory Allan Boss Executive VP-Legal & Group General Counsel 60 2013
Members of the board
Name Title Age Since
Brian McNamee Chairman 64 2018
Bruce Brook Independent Non-Executive Director 65 2011
Marie McDonald Independent Non-Executive Director 65 2013
Megan Clark, Dr. Independent Non-Executive Director 63 2016
Carolyn Judith Hewson Independent Non-Executive Director 66 2019
Duncan John Maskell, Dr. Independent Non-Executive Director - 2021
Alison Watkins Independent Non-Executive Director 56 2021
Andrew Cuthbertson Executive Director 66 2018
Paul Perreault Chief Executive Officer, Executive Director & MD 63 2013
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 478,748,391 454,807,152 95.0% 0 0.0% 95.0%
Shareholders
NameEquities%
BlackRock Fund Advisors 14,104,126 2.93%
The Vanguard Group, Inc. 11,382,254 2.36%
Norges Bank Investment Management 6,996,634 1.45%
BlackRock Investment Management (Australia) Ltd. 4,626,484 0.96%
WCM Investment Management LLC 4,334,728 0.90%
BlackRock Advisors (UK) Ltd. 3,428,750 0.71%
First Sentier Investors (Australia) IM Ltd. 3,241,378 0.67%
BlackRock Investment Management (UK) Ltd. 3,213,086 0.67%
Capital Research & Management Co. (World Investors) 3,143,935 0.65%
Scout Investments, Inc. 2,435,114 0.51%
Holdings
NameEquities%Valuation
VIFOR PHARMA AG (VIFN) 15,171,862 23.3% 2,711,912,679 USD
Company contact information
CSL Ltd.
45 Poplar Road
Parkville, Victoria (VIC) 3052

Phone : +61.3.9389.1911
Fax : +61.3.9389.1434
Web : http://www.csl.com.au
Brand Portfolio
In partnership withAllbrands.markets
More brands of CSL Limited